Mauna Kea Technologies Recognizes Dr. Robert Danbert as Top U.S. User of Cellvizio

Dr. Danbert used Cellvizio in more than 300 cases in 2016

San Angelo - TX - *Press Release

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, today recognizes Robert Danbert, D.O., of the San Angelo Community Medical Center as the top U.S. user in 2016 of Cellvizio®, the Company’s flagship product for optical biospy.

Cellvizio is an endomicroscopy system that generates optical biopsies to provide physicians with minimally-invasive, microscopic images of tissue. Dr. Danbert uses Cellvizio as a diagnostic tool for the majority of his gastroenterology cases, most often to monitor patients with gastroesophageal reflux disease (GERD) to determine changes in their esophageal lining. Monitoring is important because in some cases esophageal tissue can morph into tissue resembling the intestine, resulting in a diagnosis of Barrett's esophagus, which is associated with an increased risk of developing esophageal cancer. Cellvizio real-time images can be easily identified by the physician allowing him to identify precancerous cells that can be treated to prevent esophageal cancer.

Dr. Danbert commented, “Barrett’s esophagus is significant because it is a precursor to esophageal adenocarcinoma, which has a rapidly increasing incidence and a high mortality rate in the U.S. – with a 3-year survival rate of only 20%.1 In my experience, Cellvizio offers a minimally-invasive option for directly seeing under microscope in real-time the cells lining the esophagus, improving initial biopsy and diagnosis thus avoiding too many invasive procedures for biopsies and reducing repeating those procedure in GERD patients. We have implemented Cellvizio as a routine exam in our practice to improve patient surveillance and diagnosis and overall help us make the best possible recommendations for GERD patient management and treatment.”

Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies, added, “We are proud to have a physician such as Dr. Danbert routinely utilize our optical biopsy technology to improve diagnostic yield through better targeting and accuracy based on real-time optical feedback. Cellvizio has benefited more than 300 patients in 2016 alone with Dr. Danbert and we look forward to continued Cellvizio use for patient surveillance and to reliably monitor and manage patient treatment going forward.”

More Stories

Don't Miss

Latest News